



February 15, 2012

Dear Health Care Professional:

I am writing to request your assistance in identifying and referring patients to a study that will evaluate varenicline, bupropion and nicotine replacement patches as aids to smoking cessation treatment in subjects with and without a mental health disorder and to characterize the neuropsychiatric safety profile in these patients. This is a late phase clinical trial.

Potential subjects must be between the ages of 18 and 75, be current smokers who smoke 10 or more cigarettes per day and are motivated to quit smoking. Subjects who qualify would be expected to participate in the study for 24 weeks, with attendance to 15 outpatient visits and 11 telephone visits.

If you think any of your patients might be interested in obtaining more information, I would be happy to provide study information brochures for distribution. Alternatively, if you think it is appropriate, your patients are welcome to contact my research staff directly. My staff will be glad to answer any questions that your patients may have regarding this research study (EAGLES).

Please feel free to contact me or Jennifer Ferguson, Research Manager at (713) 563-7718 if you have any questions about this study or if you would be interested in receiving additional study information brochures for your patients. Please feel free to provide your patients with the research line (713) 792-2265 for your patients to contact us directly.

Thank you for your consideration.

Sincerely,

Maher A. Karam, M.D.
Associate Professor, Addiction Psychiatrist
Associate Medical Director, Tobacco Treatment
Department of Behavioral Science
(713) 792-1113
maherkaram@mdanderson.org

Paul Cinciripini, Ph.D.
Professor & Deputy Chair
Director, Tobacco Treatment Program
Department of Behavioral Science
(713) 745-1868
pcinciri@mdanderson.org